betaine has been researched along with Cardiovascular Diseases in 50 studies
glycine betaine : The amino acid betaine derived from glycine.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (20.00) | 29.6817 |
| 2010's | 18 (36.00) | 24.3611 |
| 2020's | 18 (36.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosas-Rodríguez, JA | 1 |
| Valenzuela-Soto, EM | 1 |
| Golzarand, M | 1 |
| Mirmiran, P | 1 |
| Azizi, F | 1 |
| Amrein, M | 1 |
| Li, XS | 1 |
| Walter, J | 1 |
| Wang, Z | 6 |
| Zimmermann, T | 1 |
| Strebel, I | 1 |
| Honegger, U | 1 |
| Leu, K | 1 |
| Schäfer, I | 1 |
| Twerenbold, R | 1 |
| Puelacher, C | 1 |
| Glarner, N | 1 |
| Nestelberger, T | 1 |
| Koechlin, L | 1 |
| Ceresa, B | 1 |
| Haaf, P | 1 |
| Bakula, A | 1 |
| Zellweger, M | 1 |
| Hazen, SL | 5 |
| Mueller, C | 1 |
| Fretts, AM | 1 |
| Jensen, P | 1 |
| Budoff, M | 1 |
| Sitlani, CM | 1 |
| Wang, M | 2 |
| de Oliveira Otto, MC | 1 |
| DiDonato, JA | 2 |
| Lee, Y | 1 |
| Psaty, BM | 1 |
| Siscovick, DS | 1 |
| Sotoodehnia, N | 1 |
| Tang, WHW | 1 |
| Lai, H | 1 |
| Lemaitre, RN | 1 |
| Mozaffarian, D | 1 |
| Díez-Ricote, L | 2 |
| San-Cristobal, R | 1 |
| Concejo, MJ | 1 |
| Martínez-González, MÁ | 2 |
| Corella, D | 2 |
| Salas-Salvadó, J | 2 |
| Goday, A | 1 |
| Martínez, JA | 1 |
| Alonso-Gómez, ÁM | 1 |
| Wärnberg, J | 1 |
| Vioque, J | 1 |
| Romaguera, D | 1 |
| López-Miranda, J | 1 |
| Estruch, R | 2 |
| Tinahones, FJ | 1 |
| Lapetra, J | 2 |
| Serra-Majem, L | 2 |
| Bueno-Cavanillas, A | 1 |
| Tur, JA | 1 |
| Martín Sánchez, V | 1 |
| Pintó, X | 1 |
| Gaforio, JJ | 1 |
| Matía-Martín, P | 1 |
| Vidal, J | 1 |
| Mas Fontao, S | 1 |
| Ros, E | 2 |
| Vázquez-Ruiz, Z | 1 |
| Ortega-Azorín, C | 1 |
| García-Gavilán, JF | 1 |
| Malcampo, M | 1 |
| Martínez-Urbistondo, D | 1 |
| Tojal-Sierra, L | 1 |
| García Rodríguez, A | 1 |
| Gómez-Bellvert, N | 1 |
| Chaplin, A | 1 |
| García-Ríos, A | 1 |
| Bernal-López, RM | 1 |
| Santos-Lozano, JM | 1 |
| Basterra-Gortari, J | 1 |
| Sorlí, JV | 1 |
| Murphy, M | 1 |
| Gasulla, G | 1 |
| Micó, V | 2 |
| Salaverria-Lete, I | 1 |
| Goñi Ochandorena, E | 1 |
| Babio, N | 1 |
| Herraiz, X | 1 |
| Ordovás, JM | 2 |
| Daimiel, L | 2 |
| Ruiz-Valderrey, P | 1 |
| Blanco, R | 1 |
| Tomé-Carneiro, J | 1 |
| Dávalos, A | 1 |
| Liu, S | 1 |
| Wang, D | 1 |
| Li, B | 2 |
| Li, K | 1 |
| Dai, X | 1 |
| Cheng, L | 1 |
| Wang, J | 7 |
| Huang, T | 1 |
| Tang, Y | 1 |
| Xiao, Y | 1 |
| Yang, Q | 2 |
| Han, H | 1 |
| Sun, Z | 1 |
| Liu, L | 3 |
| Zheng, X | 1 |
| Meng, Z | 1 |
| Tao, N | 1 |
| Liu, J | 3 |
| Eyupoglu, ND | 1 |
| Caliskan Guzelce, E | 1 |
| Acikgoz, A | 1 |
| Uyanik, E | 1 |
| Bjørndal, B | 1 |
| Berge, RK | 3 |
| Svardal, A | 2 |
| Yildiz, BO | 1 |
| Fu, BC | 1 |
| Hullar, MAJ | 1 |
| Randolph, TW | 1 |
| Franke, AA | 1 |
| Monroe, KR | 1 |
| Cheng, I | 1 |
| Wilkens, LR | 1 |
| Shepherd, JA | 1 |
| Madeleine, MM | 1 |
| Le Marchand, L | 1 |
| Lim, U | 1 |
| Lampe, JW | 1 |
| Cappuccilli, M | 1 |
| Bergamini, C | 1 |
| Giacomelli, FA | 1 |
| Cianciolo, G | 1 |
| Donati, G | 1 |
| Conte, D | 1 |
| Natali, T | 1 |
| La Manna, G | 1 |
| Capelli, I | 1 |
| Meyer, KA | 3 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 2 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Xue, L | 1 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 2 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 1 |
| Wu, Y | 4 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 3 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 2 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 5 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 2 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 1 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 3 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Ebert, T | 1 |
| Painer, J | 1 |
| Bergman, P | 2 |
| Qureshi, AR | 2 |
| Giroud, S | 1 |
| Stalder, G | 1 |
| Kublickiene, K | 1 |
| Göritz, F | 1 |
| Vetter, S | 1 |
| Bieber, C | 1 |
| Fröbert, O | 1 |
| Arnemo, JM | 1 |
| Zedrosser, A | 1 |
| Redtenbacher, I | 1 |
| Shiels, PG | 1 |
| Johnson, RJ | 1 |
| Stenvinkel, P | 2 |
| Ashtary-Larky, D | 1 |
| Bagheri, R | 1 |
| Ghanavati, M | 1 |
| Asbaghi, O | 1 |
| Tinsley, GM | 1 |
| Mombaini, D | 1 |
| Kooti, W | 1 |
| Kashkooli, S | 1 |
| Wong, A | 1 |
| Pan, XF | 1 |
| Yang, JJ | 1 |
| Shu, XO | 1 |
| Moore, SC | 1 |
| Palmer, ND | 1 |
| Guasch-Ferré, M | 2 |
| Herrington, DM | 1 |
| Harada, S | 1 |
| Eliassen, H | 1 |
| Wang, TJ | 1 |
| Gerszten, RE | 1 |
| Albanes, D | 1 |
| Tzoulaki, I | 1 |
| Karaman, I | 1 |
| Elliott, P | 1 |
| Wagenknecht, LE | 1 |
| Zheng, W | 1 |
| Cai, Q | 1 |
| Matthews, CE | 1 |
| Menni, C | 1 |
| Lipworth, LP | 1 |
| Ose, J | 1 |
| Fornage, M | 1 |
| Ulrich, CM | 1 |
| Yu, D | 1 |
| Zhong, C | 1 |
| Miao, M | 1 |
| Che, B | 1 |
| Du, J | 1 |
| Wang, A | 1 |
| Peng, H | 1 |
| Bu, X | 1 |
| Ju, Z | 1 |
| He, J | 1 |
| Gillies, NA | 1 |
| Franzke, B | 1 |
| Wessner, B | 1 |
| Schober-Halper, B | 1 |
| Hofmann, M | 1 |
| Oesen, S | 1 |
| Tosevska, A | 1 |
| Strasser, EM | 1 |
| Roy, NC | 1 |
| Milan, AM | 1 |
| Cameron-Smith, D | 1 |
| Wagner, KH | 1 |
| Zheng, Y | 1 |
| He, JQ | 1 |
| Roe, AJ | 1 |
| Zhang, S | 1 |
| Bhadelia, RA | 1 |
| Johnson, EJ | 1 |
| Lichtenstein, AH | 1 |
| Rogers, GT | 1 |
| Rosenberg, IH | 1 |
| Smith, CE | 1 |
| Zeisel, SH | 4 |
| Scott, TM | 1 |
| Haissman, JM | 1 |
| Haugaard, AK | 1 |
| Ostrowski, SR | 1 |
| Hov, JR | 2 |
| Trøseid, M | 2 |
| Nielsen, SD | 1 |
| Shea, JW | 1 |
| Hu, FB | 1 |
| Ruiz-Canela, M | 1 |
| Bulló, M | 1 |
| Toledo, E | 1 |
| Wang, DD | 1 |
| Gómez-Gracia, E | 1 |
| Fiol, M | 1 |
| Fitó, M | 1 |
| Arós, F | 1 |
| Dennis, C | 1 |
| Liang, L | 1 |
| Clish, CB | 1 |
| Kang, SS | 1 |
| Rosenson, RS | 1 |
| Tang, WH | 3 |
| Levison, BS | 3 |
| Koeth, RA | 2 |
| Britt, EB | 3 |
| Fu, X | 3 |
| Schartum-Hansen, H | 1 |
| Ueland, PM | 2 |
| Pedersen, ER | 1 |
| Meyer, K | 1 |
| Ebbing, M | 1 |
| Bleie, Ø | 1 |
| Svingen, GF | 1 |
| Seifert, R | 1 |
| Vikse, BE | 1 |
| Nygård, O | 1 |
| Buffa, JA | 1 |
| Fan, Y | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Slow, S | 1 |
| Bellamy, D | 1 |
| Young, JM | 1 |
| Ho, M | 1 |
| McEntyre, CJ | 1 |
| Elmslie, JL | 1 |
| Atkinson, W | 1 |
| Molyneux, SL | 1 |
| Troughton, RW | 1 |
| Frampton, CM | 1 |
| Richards, AM | 1 |
| Chambers, ST | 1 |
| Missailidis, C | 1 |
| Hällqvist, J | 1 |
| Barany, P | 1 |
| Heimbürger, O | 1 |
| Lindholm, B | 1 |
| Obeid, R | 1 |
| Awwad, HM | 1 |
| Rabagny, Y | 1 |
| Graeber, S | 1 |
| Herrmann, W | 1 |
| Geisel, J | 1 |
| Nestvold, TK | 1 |
| Thoresen, H | 1 |
| Lappegård, KT | 1 |
| Millard, HR | 1 |
| Musani, SK | 1 |
| Dibaba, DT | 1 |
| Talegawkar, SA | 1 |
| Taylor, HA | 1 |
| Tucker, KL | 1 |
| Bidulescu, A | 1 |
| Konstantinova, SV | 1 |
| Tell, GS | 1 |
| Vollset, SE | 1 |
| Ulvik, A | 1 |
| Drevon, CA | 1 |
| Lee, JE | 1 |
| Jacques, PF | 1 |
| Dougherty, L | 1 |
| Selhub, J | 1 |
| Giovannucci, E | 1 |
| Cho, E | 1 |
| Rak, K | 1 |
| Rader, DJ | 1 |
| Klipfell, E | 1 |
| Bennett, BJ | 1 |
| Koeth, R | 1 |
| Dugar, B | 1 |
| Feldstein, AE | 1 |
| Chung, YM | 1 |
| Schauer, P | 1 |
| Smith, JD | 1 |
| Allayee, H | 1 |
| Lusis, AJ | 1 |
| Bertolo, RF | 1 |
| McBreairty, LE | 1 |
| Schwahn, BC | 1 |
| Chen, Z | 1 |
| Laryea, MD | 1 |
| Wendel, U | 1 |
| Lussier-Cacan, S | 1 |
| Genest, J | 1 |
| Mar, MH | 1 |
| Castro, C | 1 |
| Garrow, T | 1 |
| Rozen, R | 1 |
| BALL, CR | 1 |
| WILLIAMS, WL | 1 |
| COLLUM, JM | 1 |
| BORSOOK, H | 2 |
| BORSOOK, ME | 2 |
| GRAYBIEL, A | 1 |
| PATTERSON, CA | 1 |
| Craig, SA | 1 |
| Olthof, MR | 3 |
| Verhoef, P | 3 |
| van Vliet, T | 1 |
| Zock, PL | 1 |
| Katan, MB | 1 |
| Dalmeijer, GW | 1 |
| Bots, ML | 1 |
| van der Schouw, YT | 1 |
| Yap, S | 1 |
| Boers, GH | 1 |
| Wilcken, B | 1 |
| Wilcken, DE | 1 |
| Brenton, DP | 1 |
| Lee, PJ | 1 |
| Walter, JH | 1 |
| Howard, PM | 1 |
| Naughten, ER | 1 |
| Desouza, C | 1 |
| Keebler, M | 1 |
| McNamara, DB | 1 |
| Fonseca, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BASEL VIII Trial - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia[NCT01838148] | 4,000 participants (Anticipated) | Observational | 2004-05-31 | Recruiting | |||
| ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis[NCT02328677] | 5,000 participants (Anticipated) | Observational | 2007-03-31 | Recruiting | |||
| Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072] | 4,071 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Effect of Choline Source and Gut Microbiota Composition on Trimethylamine-N-oxide Response in Humans[NCT04255368] | 44 participants (Actual) | Interventional | 2017-11-09 | Completed | |||
| "Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
| Does the Human Gut Microbiome Serve as a Novel Personalized Therapeutic Target for Coronary Atherosclerosis?[NCT03009565] | 800 participants (Anticipated) | Observational | 2017-01-31 | Not yet recruiting | |||
| GutHeart: Targeting Gut Microbiota to Treat Heart Failure[NCT02637167] | Phase 2 | 150 participants (Anticipated) | Interventional | 2016-03-11 | Recruiting | ||
| Impact of Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide[NCT05071196] | 70 participants (Anticipated) | Interventional | 2022-01-01 | Active, not recruiting | |||
| Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)[NCT02016430] | 150 participants (Anticipated) | Interventional | 2014-04-04 | Recruiting | |||
| Analysis of MicroBial Metabolites After Eating Refined Food[NCT04308473] | 46 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | |||
| Evaluation of Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) in Patients With Established Atherosclerotic Disease[NCT03232099] | 42 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss[NCT03515889] | 192 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Effect of Probiotic Supplementation on Endothelial Function II[NCT03267758] | 215 participants (Anticipated) | Interventional | 2018-05-15 | Recruiting | |||
| Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People[NCT02586181] | 93 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes[NCT02588898] | 212 participants (Actual) | Observational | 2009-09-30 | Completed | |||
| Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol: A Four Week Randomized Trial[NCT01817491] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus[NCT04302168] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | |||
| Impact of Diet and Gut Microbiota on Trimethylamine-N-oxide Production and Fate in Humans[NCT02558673] | 40 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)[NCT03039023] | 86 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| The Effects of Medium-term Oral Guanidinoacetic Acid (GAA) Administration on Human Performance, Body Composition, and Metabolic Outcomes in Physically Active Men and Women[NCT01133899] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 502 |
| Active Antihypertensive Treatment | 500 |
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks
| Intervention | participants (Number) |
|---|---|
| Usual Care | 681 |
| Active Antihypertensive Treatment | 683 |
Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months
| Intervention | MoCA score (Median) |
|---|---|
| Usual Care | 22 |
| Active Antihypertensive Treatment | 22 |
Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months
| Intervention | MMSE score (Median) |
|---|---|
| Usual Care | 26 |
| Active Antihypertensive Treatment | 26 |
Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months
| Intervention | Score on modified Rankin scale (Median) |
|---|---|
| Usual Care | 1.0 |
| Active Antihypertensive Treatment | 1.0 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 68 |
| Usual Care | 54 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Usual Care | 59 |
| Active Antihypertensive Treatment | 48 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 28 |
| Usual Care | 43 |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Reduced Fat Vegan Diet | 0.22 |
| American Heart Association Diet | -0.16 |
Body mass index z-scores, also called BMI standard deviation (s.d.) scores, are measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI z-score (or its equivalent BMI-for-age percentile) can be determined. Negative BMI z-scores indicate a BMI that is lower than the population mean, while positive BMI scores indicate a value that is higher than the population mean. A decrease in the BMI z-score over time indicate a lowering of the BMI. Z-scores of 1.03 and 1.64 correspond to the 85th and 95th percentiles of BMI-for-age, which are the definitions of overweight and obesity in children. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | Z Score (Mean) |
|---|---|
| Reduced Fat Vegan Diet | -0.14 |
| American Heart Association Diet | -0.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | Z score (Mean) |
|---|---|
| PB/AHA | -0.13 |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PB/AHA | 0.39 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Children Systolic BP | Parents Systolic BP | Children Diastolic BP | Parent Diastolic BP | |
| American Heart Association Diet | -5.14 | -3.14 | -4.36 | -6.64 |
| Reduced Fat Vegan Diet | -6.43 | -7.96 | -2.61 | -3.46 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -0.08 | -0.73 |
| Reduced Fat Vegan Diet | -1.12 | -1.29 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| Children Waist Circumference | Parents Waist Circumference | Children Midarm Circumference | Parents Midarm Circumference | |
| American Heart Association Diet | -2.96 | -0.49 | -1.14 | 0.35 |
| Reduced Fat Vegan Diet | -1.53 | -1.94 | -2.02 | -1.32 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -.64 | -5.43 |
| Reduced Fat Vegan Diet | 0.93 | 4.93 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 0.21 | 0.14 |
| Reduced Fat Vegan Diet | 0.17 | -0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 2.78 | 0.21 |
| Reduced Fat Vegan Diet | -2.09 | -0.24 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -0.19 | -0.19 |
| Reduced Fat Vegan Diet | -0.17 | 0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | uU/ml (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | 3.16 | -3.15 |
| Reduced Fat Vegan Diet | -5.42 | -3.11 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| total cholesterol children | triglycerides children | high-density lipoprotein cholesterol children | low-density lipoprotein cholesterol children | total cholesterol parents | triglycerides parents | high-density lipoprotein cholesterol parents | low-density lipoprotein cholesterol parents | |
| American Heart Association Diet | -16.50 | -13.14 | -2.93 | -11.00 | -7.14 | 16.86 | 16.86 | -5.50 |
| Reduced Fat Vegan Diet | -22.50 | -25.50 | -5.93 | -13.14 | -33.79 | 6.21 | -8.14 | -27.00 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| alanine aminotransferase (ALT) children | aspartate aminotransferase (AST) children | alanine aminotransferase (ALT) parents | aspartate aminotransferase (AST) parents | |
| American Heart Association Diet | -1.14 | 0.00 | 4.57 | 4.43 |
| Reduced Fat Vegan Diet | 0.79 | 2.79 | 0.86 | 0.14 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -69.23 | 1.78 |
| Reduced Fat Vegan Diet | -75.34 | 16.91 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -1.55 | -2.01 |
| Reduced Fat Vegan Diet | -3.05 | -3.64 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Children adj mean ratio systolic BP | Children adj mean ratio diastolic BP | parents adj mean ratio systolic BP | parents adj mean ratio diastolic BP | |
| PB/AHA | 1.87 | 1.01 | 0.97 | 1.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | percentile (Mean) | |
|---|---|---|
| Children Change in BMI | Parents Change in BMI | |
| PB/AHA | -1.17 | -0.69 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| children waist circumference | parents waist circumference | children arm circumference | parents arm circumference | |
| PB/AHA | 1.32 | -1.14 | -1.25 | -1.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children Weight | Parents Weight | |
| PB/AHA | -1.71 | -1.95 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| CHOL children | TRIG children | HDL children | LDL children | CHOL parents | TRIG parents | HDL parents | LDL parents | |
| PB/AHA | -10.34 | 1.01 | 0.17 | 0.95 | -27.29 | 0.95 | 0.94 | -21.92 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 1.01 | 1.06 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.99 | 0.96 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.46 | 0.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.26 | 1.14 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.7 | 0.87 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| ALT children | AST children | ALT parents | AST parents | |
| PB/AHA | 1 | 1.13 | 0.85 | 0.83 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.95 | 0.93 |
Changes in levels of non-labeled TMAO from baseline to Day 28 measured by established mass spectrometry techniques. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg in 24 hours (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 26.2 | 139.0 |
| Egg Whites + Choline Bitartrate Tablets | 29.3 | 186.9 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 27.5 | 221.8 |
| Phosphatidylcholine Capsules | 15.8 | 33.1 |
| Whole Hardboiled Eggs | 24.3 | 28.5 |
Changes in measured HDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 49 | 51 |
| Egg Whites + Choline Bitartrate Tablets | 48 | 50 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 57 | 56 |
| Phosphatidylcholine Capsules | 61 | 62 |
| Whole Hardboiled Eggs | 48 | 49 |
Changes in measured LDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 90 | 94 |
| Egg Whites + Choline Bitartrate Tablets | 104 | 101 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 108 | 118 |
| Phosphatidylcholine Capsules | 107 | 106 |
| Whole Hardboiled Eggs | 91 | 86 |
Changes in total cholesterol levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 180 | 172 |
| Egg Whites + Choline Bitartrate Tablets | 186 | 178 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 187 | 198 |
| Phosphatidylcholine Capsules | 175 | 172 |
| Whole Hardboiled Eggs | 156 | 158 |
Changes in measured triglyceride levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 106 | 96 |
| Egg Whites + Choline Bitartrate Tablets | 122 | 109 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 103 | 97 |
| Phosphatidylcholine Capsules | 74 | 84 |
| Whole Hardboiled Eggs | 86 | 100 |
Fasting plasma levels of betaine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 38.2 | 69.0 |
| Egg Whites + Choline Bitartrate Tablets | 38.7 | 59.8 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 30.7 | 46.9 |
| Phosphatidylcholine Capsules | 33.6 | 46.3 |
| Whole Hardboiled Eggs | 28.1 | 39.7 |
Fasting plasma levels of carnitine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 21.2 | 18.7 |
| Egg Whites + Choline Bitartrate Tablets | 21.1 | 18.9 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 21.5 | 15.6 |
| Phosphatidylcholine Capsules | 23.4 | 20.8 |
| Whole Hardboiled Eggs | 19.1 | 19.4 |
Fasting plasma levels of choline from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 7.5 | 12.9 |
| Egg Whites + Choline Bitartrate Tablets | 9.5 | 12.8 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 8.5 | 14.0 |
| Phosphatidylcholine Capsules | 7.6 | 10.6 |
| Whole Hardboiled Eggs | 8.3 | 10.9 |
Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry. (NCT03039023)
Timeframe: Baseline, 28 days
| Intervention | uM (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 1.9 | 11.1 |
| Egg Whites + Choline Bitartrate Tablets | 2.6 | 28.1 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
| Phosphatidylcholine Capsules | 2.8 | 3.4 |
| Whole Hardboiled Eggs | 2.0 | 2.3 |
The activation and functioning of platelets within a single subject will be compared before and after increased choline intake. (NCT03039023)
Timeframe: Baseline, Day 28
| Intervention | aggregation percentage (Median) | |
|---|---|---|
| Baseline | Day 28 | |
| Choline Bitartrate Tablets | 2.6 | 12.8 |
| Egg Whites + Choline Bitartrate Tablets | 3.0 | 29.4 |
| Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
| Phosphatidylcholine Capsules | 2.8 | 3.4 |
| Whole Hardboiled Eggs | 2.6 | 3.6 |
12 reviews available for betaine and Cardiovascular Diseases
| Article | Year |
|---|---|
The glycine betaine role in neurodegenerative, cardiovascular, hepatic, and renal diseases: Insights into disease and dysfunction networks.
Topics: Betaine; Cardiovascular Diseases; Cell Size; Humans; Hyperhomocysteinemia; Kidney Diseases; Liver Di | 2021 |
Association of choline and betaine with the risk of cardiovascular disease and all-cause mortality: Meta-analysis.
Topics: Betaine; Cardiovascular Diseases; Choline; Humans; Observational Studies as Topic; Prospective Studi | 2023 |
Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery.
Topics: Betaine; Cardiovascular Diseases; Choline; Dietary Supplements; DNA Methylation; Eating; Epigenesis, | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis.
Topics: Betaine; Biomarkers; Cardiovascular Diseases; Dietary Supplements; Homocysteine; Humans; Triglycerid | 2022 |
Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies.
Topics: Adult; Aged; Betaine; Cardiovascular Diseases; Choline; Diet; Female; Humans; Male; Middle Aged; Pro | 2017 |
Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease.
Topics: Animals; Betaine; Biomarkers; Cardiovascular Diseases; Folic Acid; Genetic Predisposition to Disease | 2018 |
The nutritional burden of methylation reactions.
Topics: Animals; Betaine; Cardiovascular Diseases; Choline; Creatine; Diet; Dietary Supplements; Folic Acid; | 2013 |
Betaine in human nutrition.
Topics: Animals; Betaine; Cardiovascular Diseases; DNA Methylation; Gastrointestinal Agents; Humans; Hyperho | 2004 |
Effects of betaine intake on plasma homocysteine concentrations and consequences for health.
Topics: Animals; Betaine; Cardiovascular Diseases; Choline; Folic Acid; Homocysteine; Humans; Lipids | 2005 |
Betaine supplementation and blood lipids: fact or artifact?
Topics: Betaine; Cardiovascular Diseases; Dietary Supplements; Homocysteine; Humans; Lipids; Lipotropic Agen | 2006 |
Drugs affecting homocysteine metabolism: impact on cardiovascular risk.
Topics: Anticonvulsants; Betaine; Cardiovascular Diseases; Clinical Trials as Topic; Gonadal Steroid Hormone | 2002 |
7 trials available for betaine and Cardiovascular Diseases
| Article | Year |
|---|---|
One-year longitudinal association between changes in dietary choline or betaine intake and cardiometabolic variables in the PREvención con DIeta MEDiterránea-Plus (PREDIMED-Plus) trial.
Topics: Aged; Betaine; Cardiovascular Diseases; Choline; Diet, Mediterranean; Female; Humans; Male; Mediterr | 2022 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Nutritional supplementation alters associations between one-carbon metabolites and cardiometabolic risk profiles in older adults: a secondary analysis of the Vienna Active Ageing Study.
Topics: Aged; Aging; Betaine; Carbon; Cardiovascular Diseases; Choline; Dietary Supplements; Female; Homocys | 2022 |
Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study.
Topics: Aged; Aged, 80 and over; Betaine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Chi-Squ | 2017 |
Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients.
Topics: Aged; Betaine; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes | 2013 |
Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans.
Topics: Adult; Aged; Betaine; Cardiovascular Diseases; Female; Folic Acid; Homocysteine; Humans; Lipids; Lip | 2005 |
Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study.
Topics: Adolescent; Adult; Aged; Betaine; Cardiovascular Diseases; Child; Child, Preschool; Comorbidity; Dru | 2001 |
32 other studies available for betaine and Cardiovascular Diseases
| Article | Year |
|---|---|
Association between dietary choline and betaine intake and 10.6-year cardiovascular disease in adults.
Topics: Adult; Betaine; Cardiovascular Diseases; Choline; Cohort Studies; Diet; Humans; Iran; Prospective St | 2022 |
Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD).
Topics: Betaine; Cardiovascular Diseases; Carnitine; Choline; Coronary Artery Disease; Gastrointestinal Micr | 2022 |
Association of Trimethylamine N-Oxide and Metabolites With Mortality in Older Adults.
Topics: Aged; Betaine; Cardiovascular Diseases; Carnitine; Choline; Cohort Studies; Female; Humans; Male; Me | 2022 |
TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Cardiovascular Diseases; Carnitine; Choline; Humans; Inflammation | 2022 |
Dietary betaine intake and risk of mortality in patients with coronary artery disease: the prospective Guangdong Coronary Artery Disease Cohort.
Topics: Betaine; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Diet; Humans; Methionine; | 2023 |
Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome.
Topics: Adolescent; Adult; Betaine; Blood Glucose; Cardiovascular Diseases; Carnitine; Choline; Female; Gast | 2019 |
Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study.
Topics: Adiposity; Aged; Bacteria; Betaine; Biomarkers; Cardiovascular Diseases; Carnitine; Choline; Cohort | 2020 |
Population studies of TMAO and its precursors may help elucidate mechanisms.
Topics: Adiposity; Betaine; Biomarkers; Cardiovascular Diseases; Carnitine; Choline; Humans; Methylamines; M | 2020 |
Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bears.
Topics: Adult; Aged; Aged, 80 and over; Animals; Betaine; Biomimetics; Cardiovascular Diseases; Choline; Fem | 2020 |
Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis.
Topics: Betaine; Biomarkers; Cardiovascular Diseases; Carnitine; Choline; Creatinine; Cross-Sectional Studie | 2021 |
Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
Topics: Aged; Betaine; Cardiovascular Diseases; Case-Control Studies; Choline; Female; Humans; Lipotropic Ag | 2021 |
Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy.
Topics: Animals; Atherosclerosis; Betaine; Cardiomyopathies; Cardiovascular Diseases; Humans; Methylamines | 2022 |
Choline and its metabolites are differently associated with cardiometabolic risk factors, history of cardiovascular disease, and MRI-documented cerebrovascular disease in older adults.
Topics: Aged; Aged, 80 and over; Betaine; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cere | 2017 |
Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection.
Topics: Adult; Betaine; Biomarkers; Blood Platelets; Cardiovascular Diseases; Carnitine; Choline; Cross-Sect | 2017 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Betaine; Cardiovascular Diseases; Choline; Female | 2013 |
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide.
Topics: Animals; Betaine; Cardiovascular Diseases; Choline; Female; Humans; Intestinal Mucosa; Kaplan-Meier | 2014 |
Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Betaine; Biomarkers; Cardiovascular Diseases; Case | 2014 |
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease.
Topics: Adult; Aged; Betaine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Choline; Female; Fibr | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism.
Topics: Aged; Bacteria; Betaine; Cardiovascular Diseases; Choline; Creatinine; Diabetes Mellitus; Female; Ga | 2016 |
Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.
Topics: Adult; Atherosclerosis; Bariatric Surgery; Betaine; Body Mass Index; Cardiovascular Diseases; Carnit | 2016 |
Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study.
Topics: Adult; Aged; Aged, 80 and over; Betaine; Black People; Cardiovascular Diseases; Choline; Coronary Di | 2018 |
Dietary patterns, food groups, and nutrients as predictors of plasma choline and betaine in middle-aged and elderly men and women.
Topics: Aged; Betaine; Bread; Cardiovascular Diseases; Choline; Cohort Studies; Diet Surveys; Dietary Fats; | 2008 |
Are dietary choline and betaine intakes determinants of total homocysteine concentration?
Topics: Betaine; Cardiovascular Diseases; Choline; Cognition Disorders; Diet; Female; Folic Acid; Homocystei | 2010 |
Cardiovascular disease: the diet-microbe morbid union.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Choline; Diet; Dietary Fats; | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency.
Topics: Animals; Betaine; Cardiovascular Diseases; Choline; Dose-Response Relationship, Drug; Female; Genoty | 2003 |
Betaine. Monograph.
Topics: Betaine; Cardiovascular Diseases; Fatty Liver; Homocysteine; Homocystinuria; Humans; Hyperhomocystei | 2003 |
Cardiovascular lesions in Swiss mice fed a high fat-low protein diet with and without betaine supplementation.
Topics: Animals; Betaine; Cardiovascular Diseases; Diet; Diet, High-Fat; Diet, Protein-Restricted; Dietary S | 1963 |
The biochemical basis of betaine-glycocyamine therapy.
Topics: Betaine; Biochemical Phenomena; Cardiovascular Diseases; Creatine; Glycine; Humans | 1951 |
Treatment of cardiac decompensation with betaine and glycocyamine.
Topics: Betaine; Biochemical Phenomena; Cardiovascular Diseases; Creatine; Glycine; Heart Failure; Humans | 1951 |
Use of betaine and glycocyamine in the treatment of patients with heart disease: preliminary report.
Topics: Betaine; Cardiovascular Diseases; Creatine; Glycine; Heart Diseases; Humans | 1951 |
Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women.
Topics: Aged; Betaine; Cardiovascular Diseases; Choline; Cohort Studies; Diet; Female; Folic Acid; Follow-Up | 2008 |